Tests eplerenone against chlorthalidone for heart and blood vessel effects in hypertension
Compares eplerenone with chlorthalidone in adults with high blood pressure and thickened heart muscle.
Plain-language title generated from the registry record
Registry title: Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
Key facts
- Where
- Boston, United StatesSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT05593055, who can take part
Where in United States
- Brigham and Women's HospitalBoston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Brigham and Women's Hospital
- Trial code
- NCT05593055
- Record updated
- 6 April 2026
- Original description
The investigators' goal is to show that in hypertensive men and women with left ventricular hypertrophy (LVH) treatment with a mineralocorticoid receptor (MR) antagonist, versus a thiazide-like diuretic, will improve coronary microvascular function and cardiac efficiency, which will associate with improvements in LV structure and function. The investigators will achieve this through a randomized, controlled, basic experimental study involving humans (BESH).Read full original descriptionShow less
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
The investigators' goal is to show that in hypertensive men and women with left ventricular hypertrophy (LVH) treatment with a mineralocorticoid receptor (MR) antagonist, versus a thiazide-like diuretic, will improve coronary microvascular function and cardiac efficiency, which will associate with improvements in LV structure and function. The investigators will achieve this through a randomized, controlled, basic experimental study involving humans (BESH).
Inclusion: History of hypertension; Seated systolic BP < 180 mmHg and diastolic < 110 mmHg if on antihypertensives; Seated systolic BP 141-200 mmHg and/or diastolic BP 90-114 mmHg if not on antihypertensives; LVH by echocardiogram; For men: interventricular septum thickness ≥ 12mm; For women: interventricular septum thickness ≥ 11mm; We will also allow inclusion of people with treated hypothyroidism, pre-diabetes and diabetes controlled by diet, exercise, and/or metformin.
Exclusion: A history in the prior 6 months of Q-wave myocardial infarction, stroke, transient ischemic attack, percutaneous transluminal coronary angioplasty, or coronary artery bypass graft; Hormone replacement therapy; New York Heart Association class III to IV congestive heart failure or unstable angina; History of secondary hypertension; Hepatic disease; Bronchospastic lung disease; Major medical illness, including uncontrolled diabetes mellitus (Hemoglobin A1c >7.5); LV ejection fraction < 40%; Renal disease (seum creatinine >1.5 mg/dL for men and >1.3 mg/dL for women); All individuals <18 and >75 years will be excluded due to safety concerns of administering an angiotensin-II infusion in these patient groups; Use of MR antagonist (eplerenone, spironolactone, or finerenone) or amiloride (amiloride inhibits ENaC, which is a key mediator of MR's actions) within the past year; Orthostatic hypotension; Known genetic cardiomyopathy; Alcohol or substance abuse; Abnormal values for electrolytes, liver enzymes or TSH; Pregnancy or lactation.